SAN ANTONIO -
Breast-cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.
In a large international study, an experimental drug from Genentech called pertuzumab held cancer at bay for a median of 18 months when given with standard treatment, versus 12 months for others given only the usual treatment. It also strongly appears to be improving survival, and follow-up is continuing to see if it does.
"You don't see that very often. . . . It's a spectacular result," said one study leader, Sandra Swain, medical director of Washington Hospital Center's cancer institute.
In a second study, another drug long used in organ transplants but not tried against breast cancer - everolimus, sold as Afinitor by Novartis AG - kept cancer in check for a median of seven months in women whose disease was worsening despite treatment with hormone-blocking drugs. A comparison group that received only hormonal medicine had just a three-month delay in disease progression.
Afinitor works in a novel way, seems "unusually effective" and sets a new standard of care, said Peter Ravdin, breast-cancer chief at the University of Texas Health Science Center, in San Antonio. He has no role in the work or ties to drugmakers. Most patients have tumors like those in this study - their growth is fueled by estrogen.
Results, released yesterday, come a few weeks after federal approval was revoked for another Genentech drug, Avastin, that did not meaningfully help breast- cancer patients. It still is sold for other tumor types.
The new drugs are some of the first major developments since Herceptin came out in 1998. It has become standard treatment for a certain type of breast cancer.